GLP‑1s: benefits vs coverage
Emerging reports say some people don’t lose much weight on GLP‑1 drugs but still show improvements in liver and heart markers, shifting how benefits are being evaluated. (gulfcoastnewsnow.com). At the same time, several U.S. states are moving to drop Medicaid coverage for GLP‑1 weight‑loss drugs as demand rises, creating a contrast between clinical nuance and access policy. (theguardian.com)
Glucagon-like peptide-1 drugs are being judged on two tracks at once: new evidence says some patients get liver and heart benefits even without much weight loss, while states are cutting Medicaid coverage when the drugs are prescribed only for obesity. (kff.org) These medicines copy a gut hormone that lowers blood sugar and curbs appetite. They were first used for type 2 diabetes, then became major obesity drugs under brand names including Wegovy and Zepbound. (kff.org) A Cell Metabolism study published this week reported that semaglutide improved liver function in mice with metabolic dysfunction-associated steatohepatitis by acting on liver sinusoidal endothelial cells, a type of blood-vessel lining cell in the liver, and that effect did not depend on weight loss. (cell.com) That liver disease, often shortened to metabolic dysfunction-associated steatohepatitis, is a severe form of fatty liver disease that can lead to scarring, cirrhosis, liver cancer, and transplant. The American Association for the Study of Liver Diseases said in August 2025 that Wegovy became the first glucagon-like peptide-1 therapy approved by the Food and Drug Administration for adults with the disease and moderate to advanced fibrosis. (aasld.org) Clinical reporting this week also said about 10% to 15% of people on glucagon-like peptide-1 drugs are “non-responders” for substantial weight loss in trials, even as researchers keep finding benefits in heart, kidney, and liver outcomes beyond the number on the scale. (health.yahoo.com) That creates a policy mismatch in Medicaid. Kaiser Family Foundation said states must generally cover Food and Drug Administration-approved drugs under Medicaid, but a long-standing exception lets them choose whether to cover weight-loss drugs, so obesity use is optional while diabetes, cardiovascular disease, and sleep apnea indications are required. (kff.org) As of January 2026, Kaiser Family Foundation counted 13 state Medicaid fee-for-service programs covering glucagon-like peptide-1 drugs for obesity treatment. The same analysis said coverage remains limited because of high upfront costs and tighter state budgets. (kff.org) California ended Medi-Cal coverage on January 1, 2026 for glucagon-like peptide-1 medications prescribed solely for weight loss in adults, while keeping coverage available for specific non-weight-loss indications with prior authorization. (medi-calrx.dhcs.ca.gov) New Hampshire made the same change on January 1, 2026, saying its Medicaid program would no longer cover glucagon-like peptide-1 medications when prescribed only for weight loss, but would still cover them for other chronic health conditions. (nh.primetherapeutics.com) Pennsylvania ended adult Medicaid coverage for glucagon-like peptide-1 drugs used for weight loss on January 1, 2026, and South Carolina said its Medicaid program would stop covering obesity use the same month while continuing coverage for type 2 diabetes. (pa.gov) (scdailygazette.com) Kaiser Family Foundation said states are weighing immediate pharmacy costs against possible longer-term reductions in obesity-related disease spending, but those savings may take years and may not return to the Medicaid program that paid for the drugs. For patients whose prescriptions can be coded for diabetes, heart disease, sleep apnea, or liver disease, the benefit question is increasingly broader than weight alone. (kff.org)
